Silicon Valley's biotech scene looks to bounce back from Theranos' 'black eye'

NYSE Floor

When the latest batch of biotech hopefuls to emerge from Silicon Valley met earlier this month for IndieBio demo day, the usual bullishness was undercut by events elsewhere, The Guardian reports. "It sucks Theranos has given us a black eye," IndieBio founder Arvind Gupta said. Yet while the faltering performance of Theranos, the flagship of Silicon Valley's push into biotech, has dealt a blow to perceptions of the field, Gupta thinks the sector will deliver on its promises eventually. "Hype tends to precede the reality in biotech, but the reality does follow," he said. "Usually." Article

Read more on

Suggested Articles

TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.

Eric Perakslis' experience with Takeda will help facilitate a new collaboration between the two companies.

The $58 million financing round represents biopharma industry's growing interest in genomics data.